SURPASS-PEDS: Adverse Events Occurring in ≥5% of Pediatric Patients in Any Treatment Group1
A table that shows the adverse events in pediatric patients in the Mounjaro 5 mg (n=32), Mounjaro 10 mg (n=33), pooled Mounjaro (5 mg and 10 mg) (n=65), or placebo (n=34) groups. Percentages reflect the number of patients who reported at least 1 occurrence of the adverse event in the Mounjaro 5 mg group, Mounjaro 10 mg group, pooled Mounjaro (5 mg and 10 mg) group, and placebo group, respectively. Diarrhea: 8 (25%), 8 (24%), 16 (25%), and 2 (6%). Nausea: 7 (22%), 6 (18%), 13 (20%), and 3 (9%). Vomiting: 5 (16%), 4 (12%), 9 (14%), and 1 (3%). Upper abdominal pain: 2 (6%), 4 (12%), 6 (9%), and 3 (9%). Abdominal pain: 5 (16%), 1 (3%), 6 (9%), and 1 (3%). Dyspepsia: 2 (6%), 4 (12%), 6 (9%), and 0. Headache: 2 (6%), 3 (9%), 5 (8%), and 1 (3%). Oropharyngeal pain: 3 (9%), 1 (3%), 4 (6%), and 2 (6%). Cough: 3 (9%), 1 (3%), 4 (6%), and 1 (3%). Hyperglycemia: 0, 0, 0, and 5 (15%). Nasopharyngitis: 1 (3%), 2 (6%), 3 (5%), and 2 (6%). Decreased appetite: 0, 4 (12%), 4 (6%), and 0. Anxiety: 1 (3%), 2 (6%), 3 (5%), and 0. Gastroenteritis: 0, 0, 0, and 2 (6%). Injection site reaction: 0, 2 (6%), 2 (3%), and 0. Tonsillitis: 2 (6%), 0, 2 (3%), and 0.